Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

PubWeight™: 5.88‹?› | Rank: Top 1%

🔗 View Article (PMC 3278060)

Published in Chest on February 01, 2012

Authors

Gordon H Guyatt1, Elie A Akl, Mark Crowther, David D Gutterman, Holger J Schuünemann, American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel

Author Affiliations

1: Department of Clinical Epidemiology and Biostatistics, McMaster University Faculty of Health Sciences, Hamilton, ON, Canada. guyatt@mcmaster.ca

Articles citing this

(truncated to the top 100)

Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study. BMJ (2015) 3.34

Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis. J Thromb Haemost (2014) 3.12

Thromboembolic Complications and Prophylaxis Patterns in Colorectal Surgery. JAMA Surg (2015) 2.40

Addressing the limitations of the CDC guideline for prescribing opioids for chronic noncancer pain. CMAJ (2016) 1.77

Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J (2013) 1.53

A framework for crafting clinical practice guidelines that are relevant to the care and management of people with multimorbidity. J Gen Intern Med (2014) 1.46

Rethinking guidelines for VTE risk among nursing home residents: a population-based study merging medical record detail with standardized nursing home assessments. Chest (2014) 1.37

The Prophylaxis of Venous Thromboembolism. Dtsch Arztebl Int (2016) 1.36

Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med (2014) 1.34

The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol (2012) 1.25

New antiplatelet agents for cardiovascular disease. CMAJ (2013) 1.09

Practices to prevent venous thromboembolism: a brief review. BMJ Qual Saf (2013) 1.08

Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thromb J (2014) 1.05

Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacol Rev (2013) 1.04

Comparison of the Short-Term Risk of Bleeding and Arterial Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Newly Treated With Dabigatran or Rivaroxaban Versus Vitamin K Antagonists: A French Nationwide Propensity-Matched Cohort Study. Circulation (2015) 1.01

Genetic and clinical determinants influencing warfarin dosing in children with heart disease. Pediatr Cardiol (2012) 0.97

Severe sepsis and septic shock: management and performance improvement. Virulence (2013) 0.94

Pulmonary complications in patients with severe brain injury. Crit Care Res Pract (2012) 0.93

Anticoagulation in atrial fibrillation. BMJ (2014) 0.93

Prevention of venous thromboembolism, 2nd edition: Korean Society of Thrombosis and Hemostasis Evidence-based Clinical Practice Guidelines. J Korean Med Sci (2014) 0.92

Natural history of patients with congenital dysfibrinogenemia. Blood (2014) 0.92

A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. J Thromb Thrombolysis (2016) 0.91

Arterial embolism. Int J Crit Illn Inj Sci (2013) 0.89

Holmium Laser Enucleation of the Prostate: Comparison of Immediate Postoperative Outcomes in Patients with and without Antithrombotic Therapy. Curr Urol (2013) 0.89

Differences in pain management between hematologists and hospitalists caring for patients with sickle cell disease hospitalized for vasoocclusive crisis. Clin J Pain (2014) 0.88

Anticoagulation during pregnancy in patients with a prosthetic heart valve. Nat Rev Cardiol (2012) 0.88

Thrombosis and cancer. Nat Rev Clin Oncol (2012) 0.88

Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis. BMC Health Serv Res (2014) 0.87

Pharmacogenetic typing for oral anti-coagulant response among factor V Leiden mutation carriers. Indian J Hum Genet (2012) 0.87

Warfarin-induced deep vein thrombosis. Int Med Case Rep J (2014) 0.87

Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients. J Trauma Acute Care Surg (2013) 0.87

How to manage warfarin therapy. Aust Prescr (2015) 0.86

The evolution of anticoagulant therapy. Blood Transfus (2015) 0.86

Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing? Pharmacogenomics (2014) 0.86

Anticoagulation drug therapy: a review. West J Emerg Med (2015) 0.86

Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations. World J Surg (2016) 0.84

Infection and venous thromboembolism in patients undergoing colorectal surgery: what is the relationship? Dis Colon Rectum (2014) 0.84

Biomolecular markers of cancer-associated thromboembolism. Crit Rev Oncol Hematol (2013) 0.84

Blood utilization in patients with burn injury and association with clinical outcomes (CME). Transfusion (2012) 0.83

Novel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patient. Int J Gen Med (2013) 0.83

UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays. PLoS One (2015) 0.83

Comparison of warfarin therapy clinical outcomes following implementation of an automated mobile phone-based critical laboratory value text alert system. BMC Med Genomics (2014) 0.82

Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art. Front Cardiovasc Med (2015) 0.82

Determinants of venous thromboembolism among hospitalizations of US adults: a multilevel analysis. PLoS One (2015) 0.82

Alternative Medications for Medications in the Use of High-Risk Medications in the Elderly and Potentially Harmful Drug-Disease Interactions in the Elderly Quality Measures. J Am Geriatr Soc (2015) 0.82

Does thromboprophylaxis prevent venous thromboembolism after major orthopedic surgery? J Bras Pneumol (2013) 0.82

Effects of Long-Term Low-Molecular-Weight Heparin on Fractures and Bone Density in Non-Pregnant Adults: A Systematic Review With Meta-Analysis. J Gen Intern Med (2016) 0.81

Thrombo-prophylaxis in acutely ill medical and critically ill patients. Indian J Crit Care Med (2014) 0.81

Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer. PLoS One (2014) 0.81

Preoperative optimization of crohn disease. Clin Colon Rectal Surg (2013) 0.80

Procedural and indwelling complications with inferior vena cava filters: frequency, etiology, and management. Semin Intervent Radiol (2015) 0.80

Eliminating Health Care Disparities With Mandatory Clinical Decision Support: The Venous Thromboembolism (VTE) Example. Med Care (2015) 0.79

Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS One (2015) 0.79

Rate of venous thromboembolism among surgical patients in Australian hospitals: a multicentre retrospective cohort study. BMJ Open (2014) 0.79

Low molecular weight heparin once versus twice for thromboprophylaxis following esophagectomy: a randomised, double-blind and placebo-controlled trial. J Thorac Dis (2015) 0.79

Advances in our understanding of "resistance" to antiplatelet agents for prevention of ischemic stroke. Stroke Res Treat (2013) 0.79

Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism. Lung (2016) 0.79

The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR. Anatol J Cardiol (2015) 0.78

Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial. Crit Care (2014) 0.78

A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PLoS One (2016) 0.78

Prevalence of deep vein thrombosis in acutely admitted ambulatory non-surgical intensive care unit patients. BMC Res Notes (2014) 0.78

Transitions of care in anticoagulated patients. J Multidiscip Healthc (2013) 0.78

Influence of Differing Analgesic Formulations of Aspirin on Pharmacokinetic Parameters. Pharmaceutics (2015) 0.78

Aspirin and multiple sclerosis. BMC Med (2015) 0.78

Warfarin cessation is non-essential in patients undergoing total knee arthroplasty--a case-control study. J Orthop Surg Res (2015) 0.78

Postoperative management of hip fractures: interventions associated with improved outcomes. Bonekey Rep (2012) 0.78

Warfarin overdose: a 25-year experience. J Med Toxicol (2014) 0.78

Oral anticoagulants in the management of venous thromboembolism. Nat Rev Cardiol (2013) 0.78

Distinct predictors of pre- versus post-discharge venous thromboembolism after hepatectomy: analysis of 7621 NSQIP patients. HPB (Oxford) (2013) 0.78

Antithrombotic prophylaxis in major orthopaedic surgery: an historical overview and update of current recommendations. Int Orthop (2013) 0.78

Primary prophylactic aspirin use and incident stroke: reasons for geographic and racial differences in stroke study. J Stroke Cerebrovasc Dis (2013) 0.78

[Anesthesiological care in orthogeriatric co-management : Perioperative treatment of geriatric trauma patients]. Z Gerontol Geriatr (2016) 0.78

Predicting the risks of venous thromboembolism versus post-pancreatectomy haemorrhage: analysis of 13,771 NSQIP patients. HPB (Oxford) (2013) 0.77

Management of dabigatran-induced bleeding: expert statement. Wien Klin Wochenschr (2013) 0.77

Guidelines on vitamin D replacement in bariatric surgery: Identification and systematic appraisal. Metabolism (2016) 0.77

Comparison of the Risk of Gastrointestinal Bleeding among Different Statin Exposures with Concomitant Administration of Warfarin: Electronic Health Record-Based Retrospective Cohort Study. PLoS One (2016) 0.77

Physician's fear of anticoagulant therapy in nonvalvular atrial fibrillation. Am J Med Sci (2014) 0.77

Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation. J Stroke (2013) 0.77

Perioperatively acquired disorders of coagulation. Curr Opin Anaesthesiol (2015) 0.77

Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence. Drug Des Devel Ther (2014) 0.77

Feasibility of extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF). Clin Cardiol (2015) 0.77

Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies. Clin Interv Aging (2013) 0.77

Role of perioperative monitoring in diagnosis of massive intraoperative cardiopulmonary embolism. J Cardiovasc Thorac Res (2014) 0.77

Prevention of venous thrombotic events in brain injury: review of current practices. Rambam Maimonides Med J (2013) 0.77

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism. Glob Cardiol Sci Pract (2013) 0.76

Adverse events in patients initiated on dabigatran etexilate therapy in a pharmacist-managed anticoagulation clinic. Pharm Pract (Granada) (2013) 0.76

Evidence-base for aspirin as venous thromboembolic prophylaxis following joint replacement. Bone Joint Res (2014) 0.76

Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial. BMC Fam Pract (2014) 0.76

Uterine myoma as a cause of iliac vein thrombosis and pulmonary embolism: common disease, rare complication. Respirol Case Rep (2014) 0.76

Antiplatelet medications and evolving antithrombotic medication. Skeletal Radiol (2013) 0.76

Comparative safety and efficacy of antithrombotics in the management of venous thromboembolism after knee or hip replacement surgery: focus on rivaroxaban. Clin Pharmacol (2013) 0.76

Evidenced-based antithrombotic therapy for acute coronary syndromes. Diabetes (2013) 0.75

Complex Perioperative Decision-Making: Liver Resection in a Patient with Extensive Superior Vena Cava/Right Atrial Thrombus and Superior Vena Cava Syndrome. Case Rep Anesthesiol (2016) 0.75

Identification of occult deep vein thrombosis before the placement of sequential compression devices. Indian J Anaesth (2012) 0.75

Is the Pulmonary Embolism Severity Index Being Routinely Used in Clinical Practice? Thrombosis (2015) 0.75

IT-CARES: an interactive tool for case-crossover analyses of electronic medical records for patient safety. J Am Med Inform Assoc (2016) 0.75

Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial. BMC Cardiovasc Disord (2016) 0.75

Prothrombin complex concentrates utility for warfarin-associated hemorrhage. Int J Clin Exp Med (2015) 0.75

Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. J Inherit Metab Dis (2016) 0.75

Discovery of Intra-Abdominal Hemorrhage during Hernioplasty in a Patient Taking Rivaroxaban. Case Rep Surg (2015) 0.75

Articles cited by this

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 10.75

Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.99

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.57

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.29

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.02

VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.50

Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.30

Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 3.87

Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 3.56

Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.83

Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.55

Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.50

Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.50

Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.46

Articles by these authors

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol (2010) 11.77

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 10.75

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood (2011) 6.50

Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA (2010) 5.90

Systematic overview of warfarin and its drug and food interactions. Arch Intern Med (2005) 5.86

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.57

GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol (2011) 5.10

Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.02

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.82

Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med (2011) 4.59

GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol (2013) 3.58

The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med (2010) 3.47

GRADE guidelines: 5. Rating the quality of evidence--publication bias. J Clin Epidemiol (2011) 3.44

Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med (2013) 3.40

Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ (2009) 3.39

GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol (2011) 3.30

Validity of composite end points in clinical trials. BMJ (2005) 3.26

Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 3.14

Acute kidney injury after cardiac surgery: focus on modifiable risk factors. Circulation (2009) 3.10

Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ (2007) 3.06

Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med (2012) 3.05

GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol (2011) 3.02

Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med (2012) 2.91

Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.83

GRADE guidelines: 8. Rating the quality of evidence--indirectness. J Clin Epidemiol (2011) 2.83

Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost (2011) 2.75

Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ (2012) 2.69

A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med (2013) 2.68

Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.55

Indications, complications, and management of inferior vena cava filters: the experience in 952 patients at an academic hospital with a level I trauma center. JAMA Intern Med (2013) 2.52

Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med (2007) 2.50

Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.50

Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.50

Antiphospholipid syndrome. Lancet (2010) 2.47

Mitochondrial sources of H2O2 generation play a key role in flow-mediated dilation in human coronary resistance arteries. Circ Res (2003) 2.31

Predicting deep venous thrombosis in pregnancy: out in "LEFt" field? Ann Intern Med (2009) 2.26

Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest (2013) 2.24

Mitochondrial reactive oxygen species-mediated signaling in endothelial cells. Am J Physiol Heart Circ Physiol (2007) 2.24

Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation (2012) 2.16

Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ Res (2003) 2.09

Diabetes mellitus impairs vasodilation to hypoxia in human coronary arterioles: reduced activity of ATP-sensitive potassium channels. Circ Res (2003) 2.01

GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol (2012) 1.90

Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med (2005) 1.87

Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. CMAJ (2013) 1.86

GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol (2012) 1.86

Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.85

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol (2012) 1.85

Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev (2011) 1.82

The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest (2008) 1.82

Fresh frozen plasma transfusion in critically ill patients. Crit Care Med (2007) 1.81

Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med (2011) 1.78

Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol (2005) 1.76

TRPV4-mediated endothelial Ca2+ influx and vasodilation in response to shear stress. Am J Physiol Heart Circ Physiol (2009) 1.76

Measuring FMD in the brachial artery: how important is QRS gating? J Appl Physiol (1985) (2010) 1.75

Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ (2008) 1.71

Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood (2004) 1.67

Interpreting the results of patient reported outcome measures in clinical trials: the clinician's perspective. Health Qual Life Outcomes (2006) 1.64

Introduction to the ninth edition: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.63

Guidance for evidence-informed policies about health systems: assessing how much confidence to place in the research evidence. PLoS Med (2012) 1.62

Pregnancy outcomes in women with chronic kidney disease: a systematic review. Clin J Am Soc Nephrol (2011) 1.59

Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med (2002) 1.55

The mechanism of flow-induced dilation in human adipose arterioles involves hydrogen peroxide during CAD. Am J Physiol Heart Circ Physiol (2006) 1.55

L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation (2003) 1.53

A red blood cell agglutination D-dimer test to exclude deep venous thrombosis in pregnancy. Ann Intern Med (2007) 1.53

Transient receptor potential vanilloid type 4-deficient mice exhibit impaired endothelium-dependent relaxation induced by acetylcholine in vitro and in vivo. Hypertension (2009) 1.51

Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study. J Crit Care (2005) 1.50

H2O2 is the transferrable factor mediating flow-induced dilation in human coronary arterioles. Circ Res (2011) 1.49

Peroxynitrite inhibits Ca2+-activated K+ channel activity in smooth muscle of human coronary arterioles. Circ Res (2002) 1.49

Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PLoS One (2012) 1.48

Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study. Thromb Haemost (2013) 1.47

Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology (2014) 1.47

Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.46

Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. Gastroenterology (2003) 1.44

Epidemiology, mechanisms, and risks: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest (2005) 1.42

The GRADE approach and Bradford Hill's criteria for causation. J Epidemiol Community Health (2010) 1.42

Creating clinical practice guidelines we can trust, use, and share: a new era is imminent. Chest (2013) 1.42

Fetal-maternal hemorrhage detection in Ontario. Am J Clin Pathol (2003) 1.42

Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest (2005) 1.41

Postpartum management of women at increased risk of thrombosis--results of a Canadian pilot survey. J Rheumatol (2006) 1.40

Altered mitochondrial membrane potential, mass, and morphology in the mononuclear cells of humans with type 2 diabetes. Transl Res (2010) 1.40

First, do no harm: less training ≠ quality care. Am J Crit Care (2012) 1.38

Meta-analysis of randomized trials on first line and adjunctive levetiracetam. Can J Neurol Sci (2011) 1.38

Hydrogen peroxide inhibits cytochrome p450 epoxygenases: interaction between two endothelium-derived hyperpolarizing factors. Circ Res (2007) 1.36

Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.34

Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother (2008) 1.32

The effect of alternative summary statistics for communicating risk reduction on decisions about taking statins: a randomized trial. PLoS Med (2009) 1.29

Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med (2008) 1.28

Oxidative stress and potassium channel function. Clin Exp Pharmacol Physiol (2002) 1.28

Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system. Trends Pharmacol Sci (2006) 1.28